醫生表示，阿司匹林或許能夠有助對抗侵襲性乳腺癌，讓那些很難治療的腫瘤對某些抗癌藥物產生更積極的反應。

Around one in five breast cancers are triple-negative. It’s a type that hormone treatment and most targeted cancer drugs don’t work against. 

大約五分之一的乳癌病例屬于三陰性乳腺癌。激素治療和大部分針對性抗癌藥物對這種乳腺癌都沒有作用。

8,000 women are diagnosed with this type of breast cancer every year and it disproportionately affects those aged under 40 and black. They face a treatment combination of surgery, chemotherapy and radiotherapy that can come with side effects.

每年有八千名女性被診斷患上三陰性乳腺癌，而且影響到40歲以下人群和黑人族群的比例很大。這些患者接受綜合治療，包括外科手術、化學療法和放射療法，但這些治療方法可能會引起副作用。

If the clinical trial in humans using aspirin is successful, it could boost the effectiveness of the immunotherapy drug avelumab, which helps the immune system target and attack cancer. Trials on animals have been successful.

如果在人體使用阿司匹林的臨床試驗取得成功，將可以提高免疫療法藥物 avelumab 的有效性，這種藥物幫助免疫系統針對性地攻擊癌癥。目前，在動物身上的試驗已經獲得成功。

Dr Anne Armstrong, the trial lead, says that inexpensive aspirin, combined with immunotherapy, could ultimately provide a safe new way to treat breast cancer.

領導試驗的安妮·阿姆斯特朗博士指出，使用價格低廉的阿司匹林和免疫療法相結合，或許最終可以為對抗乳腺癌提供新的安全治療方法。

詞匯表

targeted 針對性的
disproportionately 不成比例地
chemotherapy 化學療法
radiotherapy 放射療法
immunotherapy 免疫療法
inexpensive 便宜的，價格低廉的

閱讀理解：請在讀完上文后，回答下列問題。

1. What proportion of cases of breast cancer are triple-negative?

2. Which demographic is most affected by triple-negative breast cancer?

3. What treatment do people who have triple-negative breast cancer usually receive?

4. Which drug’s effectiveness could be boosted by aspirin?

答案  

1. What proportion of cases of breast cancer are triple-negative?
Around one in five.

2. Which demographic is most affected by triple-negative breast cancer?
People who are under 40 and those who are black.

3. What treatment do people who have triple-negative breast cancer usually receive?
They face a treatment combination of surgery, chemotherapy and radiotherapy that can come with side effects.

4. Which drug’s effectiveness could be boosted by aspirin?
Aspirin could boost the effectiveness of the immunotherapy drug avelumab.